Congestive Heart Failure (CHF) Market Report 2025

This Congestive Heart Failure (CHF) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The congestive heart failure (CHF) market size has grown strongly in recent years. It will grow from $15.94 billion in 2024 to $17.1 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period can be attributed to the high prevalence of an aging population, the increasing incidence of cardiovascular diseases, growing awareness of heart health, rising healthcare expenditures, and the growing demand for remote patient monitoring.

The congestive heart failure (CHF) market size is expected to see strong growth in the next few years. It will grow to $22.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. In the forecast period, growth is expected to be driven by the rising adoption of digital health solutions, the increasing prevalence of hypertension, the growing rates of obesity, improved patient outcomes, and a heightened focus on personalized medicine. Key trends in the forecast period include advancements in diagnostic technologies, treatment options, imaging technologies, innovations in therapeutic approaches, and developments in wearable health devices.

The rise in cardiovascular patients is expected to drive the growth of the congestive heart failure (CHF) market. Cardiovascular health pertains to the heart and blood vessels, and their role in circulating blood and maintaining the body's overall health. The increase in cardiovascular cases is attributed to factors such as sedentary lifestyles, poor dietary habits, aging populations, and urbanization, all of which contribute to a higher demand for advanced healthcare and treatment options. CHF offers targeted solutions that enhance heart efficiency, alleviate symptoms, and prevent complications, improving patient care and overall health. For instance, in January 2023, the American College of Cardiology reported that cardiovascular disease cases reached 19.8 million in 2022. Additionally, Eastern Europe had the highest mortality rate, with 553 deaths per 100,000 people. As a result, the rise in cardiovascular cases is fueling growth in the CHF market.

Companies in the CHF market are prioritizing innovations, such as single intracoronary infusion therapies, to provide effective treatment options that enhance heart function and improve the quality of life for CHF patients. Single intracoronary infusion involves delivering medication directly into the coronary artery, targeting the heart for precise treatment of conditions such as CHF. For example, in January 2024, Bayer AG, a German pharmaceutical company, and Asklepios Biopharmaceutical, Inc., a U.S.-based biotechnology company, launched the GenePHIT Phase II trial for AB-1002, a gene therapy for CHF. This approach targets non-ischemic cardiomyopathy and represents a potential breakthrough in CHF treatment through genetic solutions. The trial, which is adaptive, double-blind, and placebo-controlled, will enroll between 90 and 150 participants who have been medically stable for at least four weeks and have a left ventricular ejection fraction between 15% and 35%.

In October 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, acquired V-Wave Ltd., an Israel-based company focused on developing innovative treatments for congestive heart failure. This acquisition strengthens Johnson & Johnson's cardiovascular MedTech portfolio, particularly in heart failure care, with the Ventura Interatrial Shunt being one of the key solutions offered by V-Wave Ltd.

Major players in the congestive heart failure (chf) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG., Medtronic Plc, Eli Lilly and Company, Canon Medical Systems Corporation, Novo Nordisk A/S, Jarvik Heart Inc., Boston Scientific Corporation, Applied Molecular Genetics Inc., Biotronik SE & Co. KG, Exelixis Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., LivaNova.

North America was the largest region in the congestive heart failure (CHF) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in congestive heart failure (CHF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the congestive heart failure (CHF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Congestive heart failure (CHF) is a chronic and progressive condition in which the heart's ability to effectively pump blood is compromised, leading to fluid buildup in the lungs, heart, liver, and other areas of the body. This results in symptoms such as shortness of breath, fatigue, swelling, and difficulty with daily activities, ultimately affecting overall quality of life and necessitating continuous medical management and treatment.

The main types of congestive heart failure (CHF) include systolic heart failure, diastolic heart failure, left-sided heart failure, and right-sided heart failure. Systolic heart failure occurs when the heart muscle is unable to pump blood efficiently, causing poor circulation. Treatment options include medications and surgery, with diagnostic methods such as electrocardiograms, echocardiograms, magnetic resonance imaging (MRI), stress tests, blood tests, and cardiac catheterization. These treatments and diagnostics are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies. They are used by a wide range of end-users, such as hospitals, specialty clinics, ambulatory surgical centers, and homecare settings.

The congestive heart failure (CHF) market research report is one of a series of new reports that provides Congestive Heart Failure (CHF) market statistics, including Congestive Heart Failure (CHF) industry global market size, regional shares, competitors with a Congestive Heart Failure (CHF) market share, detailed Congestive Heart Failure (CHF) market segments, market trends and opportunities, and any further data you may need to thrive in the Congestive Heart Failure (CHF) industry. This Congestive Heart Failure (CHF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The congestive heart failure (CHF) market consists of revenues earned by entities by providing cardiac treatment, hemodynamic monitoring, and therapeutic services. The market value includes the value of related goods such as diagnostic tools, monitoring devices, and support services. The congestive heart failure (CHF) market also includes sales of diagnostic tools, and testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.